Regarding the third candidate molecule, it was reported that TRIP6, a zyxin family member being enriched at focal adhesions [43], has been markedly upregulated in paclitaxel-resistant breast cancer MCF-7/PacR cells [27]. Here, TRIP6 is linked to breast carcinoma.